Research Article
Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
Table 2
Baseline characteristics (
).
| Characteristics | (%) | Median (range) |
| Age, years | | 71 (65–92) | 65–74 | 93 (73.2%) | | 75 | 34 (26.8%) | | Sex | | | Male | 62 (48.8%) | | Female | 65 (51.2%) | | ECOG | | | 0-1 | 74 (58.3%) | | 2 | 52 (40.9%) | | Unknown | 1 (0.8%) | | Durie-Salmon stage | | | 1 | 10 (7.9%) | | 2 | 28 (22.0%) | | 3 | 89 (70.1%) | | International staging system | | | 1 | 23 (18.1%) | | 2 | 51 (40.2%) | | 3 | 47 (37.0%) | | Unknown | 6 (4.7%) | | Lytic bone lesion | | | Yes | 112 (88.2%) | | No | 14 (11.0%) | | Hemoglobin (g/dL) | | 9.66 (5.20–16.30) | 10 | 75 (59.1%) | | 10 | 52 (40.9%) | | Platelets (×109/L) | | 195 (44–484) | 100 | 11 (8.7%) | | 100 | 117 (91.3%) | | Plasma cells in bone marrow (%) | | 43.88 (1.10–100) | 40 | 58 (45.7%) | | 40 | 65 (51.2%) | | Serum calcium (mg/dL) | | 9.35 (7.00–15.70) | 11.5 | 11 (8.7%) | | 11.5 | 115 (90.6%) | | Serum albumin (mg/dL) | | 3.28 (1.70–4.80) | 3.5 | 85 (66.9%) | | 3.5 | 42 (33.1%) | | eGFR (mL/min/1.73 m2) | | 66.60 (5.90–170.5) | 30 | 112 (88.2%) | | 30 | 15 (11.8%) | | Serum LD | | | UNL | 27 (21.3%) | | UNL | 74 (58.3%) | | Initial chemotherapy regimen | | | Conventional (CP, MP, and others) | 92 (78.0%) | | Novel agents (imid, bortezomib-based) | 26 (22.0%) | | Treatment | | | Chemotherapy | 118 (92.9%) | | No chemotherapy | 9 (7.1%) | |
|
|
ECOG, eastern cooperative oncology group; eGFR, estimated glomerular filtration rate; LD, lactate dehydrogenase; UNL, upper normal limit; CP, cyclophosphamide and prednisolone; MP, melphalan and prednisolone.
|